Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CD226-armoured CAR-T cell therapy
- Development stage
- Preclinical
- Lead developer
- QIMR Berghofer Medical Research Institute
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Administration
- Intravenous
01
Overview
CD226-armoured CAR-T cell therapy is an experimental chimeric antigen receptor (CAR) T-cell therapy being developed by Q-Gen Cell Therapeutics, the manufacturing arm of the QIMR Berghofer Medical Research Institute. The therapy involves T cells that are genetically modified to target cells expressing CD226 (also known as DNAM-1), a protein often involved in immune cell activation. This specific construct is 'armoured,' meaning it includes additional genetic modifications designed to enhance the T cells' ability to survive and function within the immunosuppressive environment of solid tumors. The program is currently in the preclinical stage of development and is being pursued in collaboration with an undisclosed partner to address various solid malignancies.
- Other names
- Q-Gen Cell Therapeutics-CD226-armoured CAR-T cell therapy-Solid tumours
02
Targets
NECTIN2 (Nectin cell adhesion molecule 2)
Beyond the preview
Go deeper on CD226-armoured CAR-T cell therapy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CD226-armoured CAR-T cell therapy.